ERBB2 and cancer: Natural killer (NK) cells, a small population (<10%) of circulating lymphocytes involved in the innate immunity, express Fc-gamma receptors on their surface and can recognize and bind to the reciprocal portion of the antibody (i.e., trastuzumab), which in turn binds to the surface of the target cell (i.e., HER2-positive cancer cell).